June 26, 2015.
GlaxoSmithKline has announced that it will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals. The €115m sale is subject to final European Commission approval, other regulatory approvals, and other customary closing conditions and is expected to close before the end of the year.
Source: GSK
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.